AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29025837 — intervention group
Group type: COMPARATOR
Intervention: Placebo, identically appearing, orally, once daily for 6 months.
Number of subjects: 96
Study 26009832 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (CD4 350‐550)
Number of subjects: 886
Study 23524153 — intervention group
Group type: EXPERIMENTAL
Intervention: Y‐graft technique
Number of subjects: 90
Study 23524153 — intervention group
Group type: COMPARATOR
Intervention: C‐graft technique
Number of subjects: 90
Study 22164492 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule Xinganbao
Number of subjects: 118
Study 22164492 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine
Number of subjects: 118
Study 19840566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 335
Study 19840566 — intervention group
Group type: COMPARATOR
Intervention: UFH plus tirofiban
Number of subjects: 335
Study 16575284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led smoking cessation program
Number of subjects: 0
Study 15474171 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger tapping
Number of subjects: 0
Study 15474171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory motion of the hand
Number of subjects: 0
Study 15474171 — intervention group
Group type: COMPARATOR
Intervention: Event‐based timing control (Wing‐Kristoffersson model)
Number of subjects: 0
Study 12713211 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school intervention focused on increasing physical activity and healthy eating, conducted twice a week for 12 weeks
Number of subjects: 54
Study 12713211 — intervention group
Group type: COMPARATOR
Intervention: Control group received a program unrelated to nutrition and physical activity over 12 weeks
Number of subjects: 54
Study 11095423 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg PEG‐OB weekly subcutaneous injections
Number of subjects: 30
Study 11095423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8628472 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTXA) 300 units
Number of subjects: 39
Study 8628472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8628472 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTXA)
Number of subjects: 39
Study 1319187 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg with thiopental sodium, fentanyl, and midazolam, maintained with 70% nitrous oxide in oxygen
Number of subjects: 44
Study 1319187 — intervention group
Group type: COMPARATOR
Intervention: End-tidal isoflurane 0.75% to 1% included in the induction regimen
Number of subjects: 44
Study 1319187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 Hz stimulation
Number of subjects: 44
Study 1319187 — intervention group
Group type: COMPARATOR
Intervention: 0.1 Hz stimulation
Number of subjects: 44
Study 2934708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (4-6 mg/mg/day) introduced at 3rd month after transplantation
Number of subjects: 58
Study 2934708 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (prednisone, azathioprine, and antilymphocyte serum)
Number of subjects: 58
Study 30900196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 80
Study 30900196 — intervention group
Group type: COMPARATOR
Intervention: Dry sterile sponges (Control)
Number of subjects: 80
Study 29364540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Number of subjects: 0
Study 29364540 — intervention group
Group type: COMPARATOR
Intervention: No tactile stimulation (Control)
Number of subjects: 0
Study 27539508 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational therapeutics for preventing oxaliplatin-induced neurotoxicity
Number of subjects: 0
Study 27539508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24713222 — intervention group
Group type: EXPERIMENTAL
Intervention: Palindrome Symmetric Tip Dialysis Catheter
Number of subjects: 302
Study 24713222 — intervention group
Group type: COMPARATOR
Intervention: HemoStar Long‐Term Hemodialysis Catheter
Number of subjects: 302
Study 23059149 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake therapy with bright light therapy and sleep time stabilization
Number of subjects: 75
Study 23059149 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 75
Study 20639039 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic pyeloplasty
Number of subjects: 39
Study 20639039 — intervention group
Group type: COMPARATOR
Intervention: Open pyeloplasty
Number of subjects: 39
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg every 2 weeks
Number of subjects: 41
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 12 mg every 4 weeks
Number of subjects: 41
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg every 4 weeks
Number of subjects: 41
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 4 mg every 2 weeks
Number of subjects: 41
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 41
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 41
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion-day adverse events
Number of subjects: 41
Study 18759308 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipegloticase antibody presence
Number of subjects: 41
Study 16060412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg
Number of subjects: 264
Study 16060412 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 264
Study 12136446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0
Study 12136446 — intervention group
Group type: COMPARATOR
Intervention: Manualized Psychodynamic Therapy
Number of subjects: 0
Study 10468098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of bed rest
Number of subjects: 0
Study 10468098 — intervention group
Group type: COMPARATOR
Intervention: 6 hours of bed rest
Number of subjects: 0
Study 7486839 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg added caffeine
Number of subjects: 12
Study 7486839 — intervention group
Group type: COMPARATOR
Intervention: Control (decaffeinated coffee without caffeine)
Number of subjects: 12
Study 2123395 — intervention group
Group type: COMPARATOR
Intervention: fentanyl 2.5 micrograms kg‐1
Number of subjects: 40
Study 2123395 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 10 micrograms kg‐1
Number of subjects: 40
Study 6996986 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan Depot Perlongetten)
Number of subjects: 16
Study 6996986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31215092 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (escalating daily doses from 400 to 4800 IU)
Number of subjects: 0
Study 31215092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31215092 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 28161080 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention (10 sessions involving psychoeducation, relaxation exercises, sensate focus, and gradual exposure with dilators)
Number of subjects: 77
Study 28161080 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WCG)
Number of subjects: 77
Study 26156272 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 60
Study 26156272 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio distraction
Number of subjects: 60
Study 26156272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 24131168 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 28
Study 24131168 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) administration
Number of subjects: 28
Study 21725236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside‐enhanced cardiopulmonary resuscitation
Number of subjects: 40
Study 21725236 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation
Number of subjects: 40
Study 21725236 — intervention group
Group type: COMPARATOR
Intervention: Active compression‐decompression cardiopulmonary resuscitation + impedance threshold device
Number of subjects: 40
Study 18344024 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (three cycles of 3-weekly FEC(100) then three cycles of 3-weekly Doc 100 mg/m(2))
Number of subjects: 117
Study 18344024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense treatment (four 10- to 11-day cycles of FEC(75) then four 2-weekly cycles of Doc 75 mg/m(2))
Number of subjects: 117
Study 18344024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense treatment (Doc given after FEC)
Number of subjects: 117
Study 18344024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense treatment
Number of subjects: 117
Study 18344024 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 117
Study 16978370 — intervention group
Group type: EXPERIMENTAL
Intervention: RSGMET (4 mg rosiglitazone / 500 mg metformin, escalated to 8 mg/2 g)
Number of subjects: 526
Study 16978370 — intervention group
Group type: EXPERIMENTAL
Intervention: RSGMET
Number of subjects: 526
Study 16978370 — intervention group
Group type: COMPARATOR
Intervention: MET (500 mg, escalated to 3 g)
Number of subjects: 526
Study 16978370 — intervention group
Group type: COMPARATOR
Intervention: MET
Number of subjects: 526
Study 15325604 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sphincterotomy
Number of subjects: 80
Study 15325604 — intervention group
Group type: COMPARATOR
Intervention: Closed sphincterotomy
Number of subjects: 80
Study 15325604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anal fissure before treatment
Number of subjects: 80
Study 15325604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients cured after 2 years
Number of subjects: 80
Study 15325604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recurrent fissure
Number of subjects: 80
Study 11843992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) oral suspension (250 mg/5 mL twice daily)
Number of subjects: 261
Study 11843992 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) oral suspension (160/800 mg/20 mL twice daily)
Number of subjects: 261
Study 9763553 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 10
Study 9763553 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII/von Willebrand factor (FVIII/vWF) concentrate
Number of subjects: 10
Study 9763553 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous Ig (IVIg) (1 g/kg/d for 2 days)
Number of subjects: 10
Study 9763553 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term IVIg therapy (repeated single infusions every 21 days)
Number of subjects: 10
Study 9763553 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 10
Study 9763553 — intervention group
Group type: COMPARATOR
Intervention: DDAVP and FVIII/vWF concentrates
Number of subjects: 10
Study 7852605 — intervention group
Group type: EXPERIMENTAL
Intervention: standard eye movement desensitization (EMD)
Number of subjects: 23
Study 7852605 — intervention group
Group type: EXPERIMENTAL
Intervention: variant of EMD with light tracking task
Number of subjects: 23
Study 7852605 — intervention group
Group type: EXPERIMENTAL
Intervention: variant of EMD with fixed visual attention
Number of subjects: 23
Study 3290034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous glucagon (50 patients)
Number of subjects: 103
Study 3290034 — intervention group
Group type: COMPARATOR
Intervention: Control group without glucagon (53 patients)
Number of subjects: 103
Study 7679164 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, three times daily for 3 days)
Number of subjects: 8
Study 27993 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine/flunitrazepam
Number of subjects: 150
Study 27993 — intervention group
Group type: COMPARATOR
Intervention: ketamine/diazepam
Number of subjects: 150
Study 27993 — intervention group
Group type: COMPARATOR
Intervention: ketamine/placebo
Number of subjects: 150
Study 30241951 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-frequency stimulation of the substantia nigra pars reticulata (LF-SNr) and high-frequency stimulation of the subthalamic nucleus (HF-STN)
Number of subjects: 6
Study 30241951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation of the subthalamic nucleus (HF-STN)
Number of subjects: 6
Study 30241951 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency stimulation of the substantia nigra pars reticulata (LF-SNr)
Number of subjects: 6
Study 28468607 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LIA (Local Infiltration Analgesia) with 30 mL saline, ropivacaine 2 mg/mL (300 mg), ketorolac 30 mg, adrenaline 0.5 mg
Number of subjects: 56
Study 28468607 — intervention group
Group type: COMPARATOR
Intervention: Group FNB (Femoral Nerve Block) with 30 mL ropivacaine 7.5 mg/mL (225 mg) and 151.5 mL saline
Number of subjects: 56
Study 26073387 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 60 mg daily (increased to 120 mg, 180 mg, and 240 mg at 2-week intervals)
Number of subjects: 56
Study 26073387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26073387 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002
Number of subjects: 56
Study 26073387 — intervention group
Group type: COMPARATOR
Intervention: ETC-1002 and Placebo
Number of subjects: 56
Study 24173676 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 ml 0.5% levobupivacaine plus 4 mg dexamethasone (group 1)
Number of subjects: 70
Study 24173676 — intervention group
Group type: COMPARATOR
Intervention: 25 ml 0.5% levobupivacaine plus 1 ml saline (group 2)
Number of subjects: 70
Study 22679695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (0.3 mg) or bevacizumab (0.625 mg/0.025 ml) with conventional diode laser photocoagulation (Group A)
Number of subjects: 87
Study 22679695 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy combined with cryotherapy (Group B)
Number of subjects: 87
Study 19041224 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) (50 mg/d), vitamin E (50 mg/d), and selenium (48 mug/d)
Number of subjects: 58
Study 19041224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy lecithin)
Number of subjects: 58
Study 18158596 — intervention group
Group type: EXPERIMENTAL
Intervention: FDT software version 3.0
Number of subjects: 100
Study 18158596 — intervention group
Group type: COMPARATOR
Intervention: FDT software version 2.6
Number of subjects: 100
Study 12817656 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 4
Study 12817656 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 4
Study 11068970 — intervention group
Group type: COMPARATOR
Intervention: Mother program
Number of subjects: 240
Study 11068970 — intervention group
Group type: COMPARATOR
Intervention: Dual-component program
Number of subjects: 240
Study 8633396 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of the International Prostate Symptom Score (IPSS)
Number of subjects: 64
Study 8633396 — intervention group
Group type: COMPARATOR
Intervention: Physician administration of the International Prostate Symptom Score (IPSS)
Number of subjects: 64
Study 1443066 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent support-group program for caregivers
Number of subjects: 0
Study 1443066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 3964987 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dietary records
Number of subjects: 151
Study 3964987 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly supplemented nutrients (iron, vitamin C, B vitamins)
Number of subjects: 151
Study 3964987 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated records measuring dietary intake
Number of subjects: 151
Study 3964987 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated records measuring total intake
Number of subjects: 151
Study 3964987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary records per individual
Number of subjects: 151
Study 30785935 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 SIMCE outcomes
Number of subjects: 1353
Study 27607734 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-Gy boost after BCS and 50-Gy WBI
Number of subjects: 1616
Study 27607734 — intervention group
Group type: COMPARATOR
Intervention: No boost after BCS and 50-Gy WBI
Number of subjects: 1616
Study 26004866 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical spermatic cord denervation
Number of subjects: 50
Study 23929061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost cognitive-behavioral motivational intervention
Number of subjects: 0
Study 23929061 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21112185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR and a psychoeducational intervention for smoking cessation
Number of subjects: 0
Study 19915217 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (2000 mg per day)
Number of subjects: 208
Study 19915217 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg per day)
Number of subjects: 208
Study 17309463 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam gel
Number of subjects: 50
Study 17309463 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50
Study 15492151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh plug repair
Number of subjects: 334
Study 15492151 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 334
Study 15492151 — intervention group
Group type: COMPARATOR
Intervention: Prolene Hernia System
Number of subjects: 334
Study 11736880 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg)
Number of subjects: 145
Study 11736880 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 145
Study 9253326 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 250 mg, i.m., every 21 days)
Number of subjects: 22
Study 9253326 — intervention group
Group type: EXPERIMENTAL
Intervention: Single s.c. implantation of 1200 mg crystalline testosterone (TPEL)
Number of subjects: 22
Study 9253326 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum OB levels in hypogonadal men
Number of subjects: 22
Study 8322988 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar blockade
Number of subjects: 30
Study 8322988 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar blockade
Number of subjects: 30
Study 8322988 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study 3531248 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 104
Study 3531248 — intervention group
Group type: COMPARATOR
Intervention: Methysergide
Number of subjects: 104
Study 31225647 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A plus occupational therapy
Number of subjects: 20
Study 31225647 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 20
Study 31501165 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with manual and GP follow-up
Number of subjects: 40
Study 31501165 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with manual and stroke nurse follow-up
Number of subjects: 40
Study 31501165 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40
Study 28436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol 2 μg/day
Number of subjects: 77
Study 26024502 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 240
Study 26024502 — intervention group
Group type: COMPARATOR
Intervention: Sham remote ischemic preconditioning (control)
Number of subjects: 240
Study 23161160 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of the whirligig (increased speed)
Number of subjects: 0
Study 23161160 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of the dancer (increased speed)
Number of subjects: 0
Study 23161160 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived animacy of the dancer
Number of subjects: 0
Study 21745059 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's Four-Step Approach (IG)
Number of subjects: 34
Study 21745059 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction (CG)
Number of subjects: 34
Study 19771284 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration and resistance training
Number of subjects: 13
Study 19771284 — intervention group
Group type: COMPARATOR
Intervention: Resistance training only
Number of subjects: 13
Study 16948806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering down omeprazole for three weeks
Number of subjects: 97
Study 16948806 — intervention group
Group type: COMPARATOR
Intervention: Constant dosage of omeprazole for three weeks
Number of subjects: 97
Study 16948806 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall discontinuation of PPIs
Number of subjects: 97
Study 16948806 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 97
Study 16948806 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum gastrin levels
Number of subjects: 97
Study 15191594 — intervention group
Group type: EXPERIMENTAL
Intervention: Image analysis method for plaque measurement
Number of subjects: 40
Study 10899492 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 50 mg/d for 3 months
Number of subjects: 100
Study 10899492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9476268 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline radiological features including distribution of joint space loss, subchondral bone production, and severity of joint space loss
Number of subjects: 463